Medical cannabis patients at work

TL;DR

Since August 2022 no BAG special permit needed – standard narcotics prescription.
Employer must accept illness-related absences and treatment (OR Art. 328).
In safety-critical roles: medical fitness-for-work / driving assessment required.
The diagnosis need not be disclosed – only work fitness is relevant.

Do I have to tell my employer?

In principle no: health diagnoses are specially protected personal data. You must only disclose what affects work fitness – e.g. side-effects limiting specific tasks.

In safety-critical roles a fitness-for-work certificate from a company doctor is advisable, without revealing the diagnosis.

Tension between the duty of care and the duty of loyalty

In Swiss employment law, two central duties clash when it comes to the use of medical cannabis. According to Article 328 of the Code of Obligations, the employer is obliged to protect the health and personal integrity of employees. If medical treatment with cannabinoid-containing medicinal products affects reaction time or the ability to concentrate, the company must assess whether the respective activity can still be carried out without danger to the person concerned or to third parties.

On the other side is the employee's duty of loyalty under Article 321a of the Code of Obligations. Employees must perform their work diligently and safeguard the employer's legitimate interests. Anyone taking medication that could impair work performance or safety must not conceal this impairment. Involving a trust physician can help in such cases to objectively assess the capacity to work without having to disclose the exact diagnosis to the employer.

Statutory duty of care of the employer to protect health in the workplace.
Duty of loyalty requires employees to report impairments relevant to driving or work.
Assessment by a trust physician protects privacy and clarifies fitness for work.
Avoidance of liability risks in the event of accidents through clear, prior agreements.

Road traffic and commuting under the influence of THC

For many employed people, commuting or using a company vehicle is an integral part of everyday professional life. In Switzerland, a strict zero-tolerance policy applies to THC in road traffic, with a statutory limit of 1.5 micrograms of THC per litre of blood. Since this limit can easily be exceeded with regular intake of medical cannabis, patients risk being accused of unfitness to drive, even with a legal medical prescription.

The Road Traffic Act does not distinguish between whether THC was consumed for recreational purposes or as a prescribed medicinal product. Anyone driving a vehicle with a level above the limit risks the revocation of their driving licence and criminal consequences. For people in transport professions, field service, or manual occupations involving vehicle use, this means that alternative areas of responsibility within the company must be sought before starting cannabis therapy.

Strict limit of 1.5 micrograms of THC per litre of blood in Swiss road traffic.
No special legal status for holders of a medical prescription when driving vehicles.
High risk of driving licence revocation when driving under the influence of medical cannabis.
Need for internal company solutions for the commute and driving-intensive professions.

Occupational prevention and individual agreements

To nip conflicts and uncertainties in the bud, establishing clear guidelines is recommended for Swiss companies. Such company agreements should regulate the handling of psychoactive substances and potent medications in general, rather than viewing cannabis in isolation. A neutral formulation ensures that no stigmatisation of chronically ill employees takes place, while at the same time seamlessly maintaining operational safety standards.

In individual cases, drawing up a written supplementary agreement has proven effective. This specifies which activities the affected person may perform during the period of therapy and which tasks must be temporarily suspended. Such agreements create legal certainty for both sides and demonstrate how the company actively supports the reintegration or retention of employees with health impairments without jeopardising smooth business operations.

Introduction of neutral company agreements for handling impairing medications.
Written supplementary agreements define permitted and restricted areas of activity.
Protection against discrimination of chronically ill employees within the team structure.
Regular review of the measures taken for their practical suitability.

The role of the trust physician in the assessment

If there are doubts about an employee's capacity to work, the employer may not arbitrarily demand medical details. Instead, in Swiss practice, the trust physician plays a key role. This physician acts as a neutral party between the interests of the company and the rights of the employee. While maintaining medical confidentiality, the trust physician assesses whether the medical treatment with medical cannabis impairs the performance of the contractually owed work. The result of this assessment is communicated to the employer only in the form of a qualitative assessment of the capacity to work, without disclosing sensitive diagnoses.

The costs of such an assessment by the trust physician are generally borne by the employer, as they initiated the examination. For employees, this procedure offers effective protection against discrimination and unjustified dismissal. At the same time, the company receives a legally secure basis for further workforce planning. Should the trust physician identify limitations, adjustments to the scope of duties must be jointly reviewed. This structured approach prevents hasty employment law actions and sustainably protects the relationship of trust within the company, while strictly complying with legal data protection requirements.

Preservation of medical confidentiality vis-à-vis the employer.
Objective assessment of the capacity to work by a neutral medical professional.
Assumption of the costs of the trust physician's examination by the company.
Avoidance of data protection violations when reviewing fitness for duty.

Distinction from recreational consumption in Swiss law

Swiss labor law and narcotics law draw a strict distinction between the consumption of cannabis for recreational purposes and medically prescribed therapy. While the unauthorized consumption of THC-containing cannabis remains illegal and can be punished with a fixed penalty, medical cannabis has been prescribable by doctors without a BAG exceptional permit since August 2022. This legal framework protects patients from criminal prosecution regarding possession, provided a valid prescription is available. In the workplace, this distinction means that proven therapeutic use must be evaluated differently from purely recreational consumption.

Despite this privileged status, a medical prescription does not exempt employees from workplace safety regulations. If employees work under the influence of medical cannabis, they must meet the same safety standards as individuals who do not take medication. The abuse of recreational cannabis during working hours justifies swift disciplinary measures up to and including termination without notice. In the case of medically supervised therapy, however, the employer's duty of care requires a benevolent assessment of potential adjustments before any consequences under labor law may be drawn.

Prescription-only medical cannabis has been legal without a BAG special permit since August 2022.
Recreational consumption of THC cannabis remains illegal and is subject to the fixed penalty system.
Heightened protective duties of the employer in cases of proven medical necessity.
Same safety requirements regarding actual performance capacity in daily work routine.

Liability risks and accident insurance in the event of incidents

If an accident occurs in the workplace under the influence of medical cannabis, the question of liability and accident insurance benefits arises. In such cases, Swiss accident insurers examine closely whether negligence or substance impairment was present. If it turns out that the ability to react was impaired by the prescribed cannabis and the employer failed to take appropriate protective measures, substantial recourse claims may arise. Both the company and the individual concerned can be held liable if safety regulations are disregarded.

To minimize this existential risk, seamless documentation of the capacity to work is essential. Employees must fulfill their duty of loyalty and report limitations in good time, while employers must respond within the scope of their duty of care. If an accident is caused by an undeclared medication that impairs driving or reaction capacity, this can be classified as gross negligence. In the worst-case scenario, this leads to a reduction in daily allowances or pensions by the responsible insurer, as well as criminal consequences for those responsible within the company.

Risk of recourse claims by the accident insurance in the event of proven impairment.
Gross negligence in the event of concealment of therapy-related limitations.
Necessity of seamless documentation of all safety agreements made.
Joint responsibility of employer and employee for accident prevention.

Practical implementation and forms of administration in the workplace

The way medical cannabis is administered has a direct impact on its acceptance and feasibility in daily professional life. While the intake of oily drops or capsules is discreet and odourless, vaporising flowers presents practical challenges for the business. In Switzerland, the strict legal provisions for the protection against passive smoking in the workplace apply here. Inhaling cannabis is generally prohibited in enclosed workspaces to avoid involuntarily exposing colleagues to the vapours.

For a smooth integration of the therapy, it is recommended to agree on fixed break times and suitable outdoor consumption areas. The storage of the medication should also be secure to prevent access by unauthorised third parties in the workplace. Employees should also ensure that the dosage is taken precisely as prescribed by the doctor to avoid unforeseen peaks in the effect. Open communication based on objective arguments about the chosen form of administration breaks down prejudices within the team and ensures the smooth running of daily work processes.

Compliance with the legal protection against passive smoking in all enclosed workspaces.
Preference for discreet forms of administration such as capsules or drops in daily office life.
Secure storage of cannabinoid-containing medicinal products to prevent access by third parties.
Definition of clear consumption locations and break regulations in consultation with superiors.

FAQ

Positive company test despite prescription – what to do?

Provide the medical certificate. The employer may not sanction therapeutic use as long as work fitness is preserved.

Am I allowed to take my prescribed medical cannabis during working hours?

The consumption of prescribed medication is generally permitted, provided that work capacity and safety in the workplace are not impaired. For activities with an increased risk potential, such as operating machinery, consumption must be discussed in advance with the employer or the occupational physician. Furthermore, when vaporising cannabis, the company's non-smoker protection regulations must be observed.

What happens in the event of a positive drug test at work despite a medical prescription?

In the case of a proven medical therapy, a positive drug test must not automatically lead to dismissal or disciplinary action. Affected individuals should immediately present the medical prescription to the employer. The employer must then assess whether the capacity to work in the specific position is still maintained. Dismissal based solely on the lawful consumption of a medication can be classified as abusive.

Can the employer demand to see my prescription or my diagnosis?

No, the employer has no right to inspect your medical records, diagnoses, or specific prescriptions, as these are protected by strict data privacy laws. The employer may only request confirmation of whether you are fit to perform the contractually agreed work. In the event of justified doubts regarding your fitness for work, the employer can arrange an examination by an independent medical examiner, who is, however, also bound by medical confidentiality.

Does a medical prescription count as an excuse in the event of an occupational accident?

No, a medical prescription for medical cannabis does not automatically exempt you from liability in the event of an occupational accident. Swiss accident insurance providers assess each incident individually to determine whether the intake of the medication impaired the ability to react and whether this was reported to the employer. If you have concealed a known impairment, this can be classified as gross negligence, leading to a reduction in benefits. Therefore, a prior assessment of work capacity is mandatory.

Can I be dismissed if I have to take medical cannabis?

Under Swiss employment law, a dismissal issued solely on the grounds of a medically necessary therapy can be classified as abusive. However, the employer may terminate the employment relationship with ordinary notice if the treatment leads to a permanent impairment of work capacity and no alternative employment is possible within the company. The decisive factor is always whether the contractually agreed performance can still be delivered in compliance with all safety regulations.

How should I react to unannounced drug tests in the workplace?

In the event of an unannounced drug test in the workplace, you should immediately point out your ongoing medical therapy and present your medical prescription. Since rapid tests generally only prove consumption, but not current fitness for work, an examination by an independent medical examiner should be requested in the event of a positive result. The employer is not permitted to sanction you immediately based on a positive test, as long as the medical indication is proven and there is no acute danger.

What role does the threshold of less than 1% THC play at work?

Cannabis products with a total THC content of less than 1% are not considered narcotics in Switzerland and are freely available for sale. For the workplace, this means that the consumption of such CBD products is legally assessed in a similar way to the consumption of caffeinated beverages, as long as no psychoactive effect occurs. Nevertheless, employees must ensure that these products do not impair concentration or fitness to drive, as the zero-tolerance limit in the blood remains strict.